PuSH - Publication Server of Helmholtz Zentrum München

Pletsch-Borba, L.* ; Wernicke, C.* ; Machann, J. ; Meyer, N.M.T.* ; Huong Nguyen, T.* ; Pohrt, A.* ; Hornemann, S.* ; Gerbracht, C.* ; Pfeiffer, A.F.H.* ; Spranger, J.* ; Mai, K.*

Increase in PUFA and protein, and decrease in carbohydrate intake improves liver fat in 12 months and the role of weight loss as a mediator: A randomized controlled trial.

Clin. Nutr. 43, 361-369 (2024)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND & AIMS: Recently, a beneficial effect of high intake of unsaturated fatty acids (UFA) and protein on intrahepatic lipids (IHL) was demonstrated over 12 months within a randomized controlled trial (the NutriAct trial). We now aimed to explore the specific macronutrient components driving this IHL improvement within this trial in middle-aged and elderly subjects (50-80 y) at risk for age-related diseases. METHODS: The NutriAct trial (n = 502) analyzed the effect of a high-protein and high-UFA diet on age related diseases including fatty liver disease. Individuals who completed 3-day food records with available IHL data both at baseline and at month 12 were included in this analysis. The impact of each macronutrient (E%) on IHL (measured by magnetic resonance spectroscopy) was analyzed by linear regression analyses and mediation analysis. Adherence in the intervention group was defined as intake at month 12 of ≥1 g protein/kg bodyweight or ≥25%E UFA intake; in the control group it was defined as intake of ≥15%E protein or ≥17%E UFA. RESULTS: 248 participants were included in the analyses (34 % male, median age 66 y). Although BMI changed similarly in both groups within 12 months (mean change -0.41 kg/m2 in the control and -0.70 kg/m2 in the intervention group, p within groups <0.001, p between groups = 0.09), IHL improved more strongly in the compliant intervention participants than in compliant controls (estimate of relative change 0.21 % (95 % CI 0.01, 0.40), p = 0.03). Participants with stronger increase in protein and PUFA intake and a greater decrease in carbohydrate intake showed a stronger improvement in IHL (estimate for linear relative change -0.04 % (95%CI -0.06, -0.02), estimate 4th quartile vs. 1st quartile -0.40 % (95%CI -0.65, -0.16), and 0.32 % (95%CI 0.05, 0.59), respectively). These associations were partially mediated by BMI changes. Increase in PUFA intake was also directly associated with IHL improvement independently of BMI changes (estimate for linear relative change -0.03 % (95%CI -0.05, -0.01)). CONCLUSIONS: Beneficial effects of increased protein and decreased carbohydrate intake on IHL are mediated by BMI changes in middle-aged and elderly subjects. The effect of high PUFA intake on IHL improvement was partly independent of weight loss. These results give insight into the understanding of a macronutrient specific effect on IHL changes in a long-term dietary intervention. CLINICAL TRIAL REGISTRATION: The trial was registered at German Clinical Trials Register (drks.de) as DRKS00010049.
Impact Factor
Scopus SNIP
Altmetric
6.600
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Ihl ; Intrahepatic Lipids ; Liver Fat ; Masld ; Mufa ; Pufa; Lipogenic Enzymes; Acid-composition; Dietary-protein; Plant Protein; Disease; Accumulation; Reduce; Implementation; Inflammation; Population
Language english
Publication Year 2024
HGF-reported in Year 2024
ISSN (print) / ISBN 0261-5614
e-ISSN 0261-5614
Quellenangaben Volume: 43, Issue: 12, Pages: 361-369 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh Eh1 3af, Midlothian, Scotland
Reviewing status Peer reviewed
POF-Topic(s) 90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502400-001
Grants Charite-Universitatsmedizin Berlin, Chariteplatz 1, Berlin
Scopus ID 85209382299
PubMed ID 39577067
Erfassungsdatum 2024-12-02